Page last updated: 2024-09-21

diphenylcarboxylate

Cross-References

ID SourceID
PubMed CID7169
CHEMBL ID1885870
CHEBI ID86919
SCHEMBL ID31888
MeSH IDM0174009

Synonyms (49)

Synonym
AC-21023
phenol, benzoate
93-99-2
nsc37086
wln: rvor
mls002608016 ,
nsc-37086
nsc 37086
einecs 202-293-2
ai3-04731
brn 1566346
diphenylcarboxylate
benzoic acid, phenyl ester
inchi=1/c13h10o2/c14-13(11-7-3-1-4-8-11)15-12-9-5-2-6-10-12/h1-10
phenyl benzoate ,
phenyl benzoate, 99%
benzoic acid phenyl ester
B0075
BMSE010254
FT-0658394
smr001526772
AKOS001445255
A844780
EN300-82943
HMS3080D03
dtxcid8028185
NCGC00257480-01
tox21_303595
dtxsid0048210 ,
cas-93-99-2
tox21_202880
NCGC00260426-01
dpcate
unii-b8a3wvz590
4-09-00-00303 (beilstein handbook reference)
b8a3wvz590 ,
SCHEMBL31888
phenyl benzoate [mi]
phenyl benzoate [inci]
chebi:86919 ,
CHEMBL1885870
J-523930
mfcd00003072
Q27159286
benzoic acid-phenyl ester
SY012912
CS-W010539
HY-W009823
Z28228413

Drug Classes (1)

ClassDescription
benzoate esterEsters of benzoic acid or substituted benzoic acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency70.97990.007215.758889.3584AID1224835
SMAD family member 2Homo sapiens (human)Potency51.99810.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency51.99810.173734.304761.8120AID1346859; AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency27.30600.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency54.48270.000221.22318,912.5098AID1259243; AID1259381
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency67.61410.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency48.97220.000817.505159.3239AID1159527
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.89110.000229.305416,493.5996AID743075
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency10.96350.001024.504861.6448AID743215
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.24340.001628.015177.1139AID1224843
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
histone deacetylase 9 isoform 3Homo sapiens (human)Potency54.48270.037617.082361.1927AID1259364; AID1259388
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (12.50)18.7374
1990's3 (37.50)18.2507
2000's1 (12.50)29.6817
2010's2 (25.00)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]